We conducted a study of unrelated donor bone marrow transplantation (BMT) in 11 children with severe thalassaemia. The conditioning regimen consisted of busulphan, cyclophosphamide and antilymphocyte globulin. All received T-cell nondepleted bone marrow. The median marrow-nucleated cell dose was 4.9 Â 10 8 /kg (range; 3.5À8.0 Â 10 8 /kg). Median time of granulocyte recovery was 16 days (range; 13-21 days), and of platelet recovery was 39 days (range; 14-196). Grade 2-4 acute graft-versus-host disease (GVHD) developed in six patients (54%), and grade 3-4 in one patient (9%). Three (27%) of 11 evaluable patients had chronic GVHD (limited stage). All 11 patients are alive without thalassaemia after a median follow-up time of 397 days (range; 171-814 days). This study lends support to consideration of unrelated donor BMT as an acceptable therapy to cure severe thalassaemia especially in patients who are young and do not yet show irreversible severe complications of iron overload.
tion; severe thalassaemia; children Allogeneic bone marrow transplantation (BMT) from a genotypically identical family donor is the only curative therapy for thalassaemia patients. The probability of finding a histocompatibility (HLA)-identical donor within the family is less than 30%. For thalassaemia patients without an HLA-identical sibling donor, there was until recently no other treatment than chronic transfusion and iron chelation. Recently, there has been a steady increase in the number of unrelated-donor BMTs in a variety of disorders, mainly due to the increase in the number of volunteer donors worldwide. The results of this type of transplantation have been reported by Hongeng et al 1 as comparable to those obtained with transplantations employing HLA-matched family donors especially in children with leukaemia. The remarkable outcomes may be attributed to many factors which include high-resolution molecular techniques for donor-recipient histocompatibility matching, improvement in graft-versus-host disease (GVHD) prophylaxis, and development of regimens to prevent cytomegalovirus (CMV), and Epstein-Barr virus infections.
1,2 Contu et al 3 reported the first successful unrelated donor BMT in one b-thalassaemia patient in 1994. These favourable results encouraged us to pursue this therapeutic modality among Thai thalassaemia patients.
Patients and methods
We studied 11 severe thalassaemia children who received unrelated donor BMT between March 2001 and December 2003. There were eight boys and three girls, with median age 3 years and 1 month (range; 1 year 3 months-11 years 5 months). Six patients had b thalassaemia/haemoglobin E disease and five had b/b thalassaemia (see Table 1 for patient profile). Prior to transplantation, all patients received a complete check-up and were categorized into one of three classes of risk according to the criteria proposed by Lucarelli et al 4 based on the extent of hepatomegaly, portal fibrosis, and the quality of pretransplantation iron chelation.
Iron overload in the liver was quantified in accordance with the definition of Sciot and portal fibrosis was defined as mild, moderate, or severe. 5 The number of patients assigned to risk-class I, II, and III was 8, 1, and 2, respectively. The patients in risk-class III were given hydroxyurea 20 mg/kg daily for at least 3 months prior to BMT to increase immune suppression in order to prevent graft rejection. 6 Pretransplantation patient characteristics are shown in Table 1 .
HLA compatibility was determined by DNA typing with high-resolution sequence-specific oligonucleotide probes for both class I and class II loci. All 11 bone marrow donors were identified within the Tzu Chi Taiwan Marrow Donor Registry.
The conditioning regimen consisted of busulphan 1 mg/kg taken every 6 h for 4 days, cyclophosphamide 50 mg/kg infused daily for 4 days and antilymphocyte globulin (Fresenius s ; HemoCare, Germany) 10 mg/kg also infused daily for 4 days. T-cell nondepleted bone marrow was infused on day 0. The median bone marrow-nucleated cell dose was 4.9 Â 10 8 /kg (range; 3.5-8.0 Â 10 8 /kg), and the median bone marrow CD34 þ cell dose was 3.3 Â 10 6 /kg (range; 0.8-6.9 Â 10 6 /kg). We did not use peripheral blood stem cells because of concern about chronic GVHD from previous report. 7 Four days before transplantation, the first eight marrow recipients received cyclosporine at a dose that was adjusted to achieve plasma concentration 250-350 ng/ml, while the last three received tracolimus at a dose that was adjusted to achieve plasma concentration 5-15 ng/ml. All received a short course of methotrexate. Patients with mild GVHD (grade 1 or 2) were treated with methylprednisolone 1-2 mg/kg daily. If GVHD remained at grade 2 for more than 7 days, or progressed, the steroid dose was increased to 5-10 mg/kg daily. A neutrophil count of more than 0.5 Â 10 9 /l for three consecutive days, or platelet count exceeding 20 Â 10 9 /l without transfusion for seven consecutive days, were taken as evidence of engraftment. Preventive treatment for Pneumocystis carinii pneumonia consisted of trimethoprim-sulphamethoxazole, 5 mg/kg/day given two times a day and 3 days a week. CMV and EBV reactivation was monitored by CMV and EBV viral load. Patients with a CMV viral load of more than 10 4 copies/ml were treated with intravenous ganciclovir and patients with an EBV viral load of more than 10 3 copies/ml were treated with rituximab.
Chimaerism was documented by in situ Y chromosome hybridization of blood samples in sex-mismatched donor/recipient pairs, by analysis of a variable number of tandem repeat (VNTR) polymorphisms and by microsatellite analysis of blood samples in the case of sexmatched pairs.
Results
Immunogenetic selection of donor/recipient pairs performed at molecular level showed that 10 of 11 donor/ recipient pairs were completely identical for HLA-A, -B, -DRB1. There was one pair mismatched for an HLA -DRB1 allele at molecular level (patient 5). All patients were successfully transplanted with complete allogeneic reconstitution. Median time for granulocyte recovery was 16 days (range; 13-21 days), whereas median time for self-sustained platelet recovery was 39 days (range; 14-196 days).
Acute GVHD, grade 2-4 developed in six patients (54%), and grade 3 to 4 in only one patient (9%). Three patients (27%) developed chronic GVHD, which was of limited severity. CMV reactivation developed in five (45%) patients (patient 1, 7, 8, 10, 11). None had CMV disease. EBV reactivation did not develop in our patients. All patients had full (100%) donor chimaerism and were alive with good performance after a median follow-up time of 397 days (range; 171-814 days) (see Table 1 for patient profile). Post transplantation complications are shown in Table 2 .
Discussion
The majority of thalassaemia patients do not have an HLA-identical donor within the family. For this reason, in recent years' BMT centres engaged in the cure of thalassaemia have been exposed to increased questioning pressure from both patients and families to explore the possibility of transplantation using alternative donors. The use of partially matched family donors carries a high risk of rejection, GVHD, and mortality, and has been confined to particular clinical situations. 8 Recently published reports indicate that outcome of unrelated donor transplantation in patients with leukaemia today is comparable with that of transplantation from identical family donors.
1,2 So far, there are only few anecdotal reports on BMT from unrelated donors in thalassaemia. 3, 9 La Nassa et al 10 from Italy reported a thalassaemia-free survival rate of 66% for 32 patients for a median time of 30 months after unrelated donor BMT. This was the only case series report available about unrelated donor BMT in thalassaemia until this present study. The result of unrelated donor BMT in our children with severe thalassaemia appears to be more favourable as thalassaemia demonstrated by the free survival rate of 100% for 11 patients for a median time of 12 months, even though we did not perform extended haplotype analysis like La Nassa et al. 10 The reason for this favourable result, probably, is the younger age in our thalassaemia patients. The present study provides an additional evidence to support the view that it is quite reasonable to consider unrelated donor BMT as an acceptable therapy to cure thalassaemia, at least for patients who are young and do not yet show irreversible severe complications of iron overload.
